


# Integration of New Approach Methods-Theory

- Chemicals nominated for Human Health Risk Assessment (HHRA) have widely varying hazard and dose-response databases
- Integration of New Approach Methods (NAM) is therefore fit-for-purpose along a decision-based gradient:
  - Data-poor chemicals  $\Rightarrow$  NAM may be a driver
  - Data-rich chemicals  $\Rightarrow$  NAM fills data gaps
  - Same/similar assays, same/similar data can be used in different ways to answer specific questions
- NAMs currently being integrated or evaluated in EPA HHRA contexts include:
  - Read across (expert-driven; category-based)
  - Transcriptomics (*in vivo* short-term animal)
  - High-throughput bioactivity
- Although not NAM per se, transparency principles of systematic review and integration of toxicity pathway (e.g., AOP or MOA) information also paramount

### **Read-Across**


### **Expert-driven read-across**

- 'Many-to-one approach'
- Approach is based on evidence across three information tiers (e.g., structural and physicochemical; toxicokinetic; and toxicity/bioactivity) to select analog(s)
- Hazard and dose-response information (e.g., point-of-departure [POD]) from single best analog used as surrogate for target chemical



### **Category based read-across**

- 'One-to-many' approach
- Based primarily on structural and physicochemical properties
- Robustness of approach dependent on density of analogs populating a category
- Highly reliant on weight-of-evidence supporting toxicity endpoints across category
- Presumes common AOP or MOA across category members



### **HHRA** application(s)

• Provisional Peer-Reviewed Toxicity Value (PPRTV) assessments; Superfund Technical Support memos to EPA Regions

# New Approach Methods in Human Health Risk Assessment

# Jason C. Lambert

U.S EPA, Office of Research and Development, National Center for Environmental Assessment - Cincinnati


surrogate for data-poor


Tox for category (A) = liver(B)= kidney, liver (C) = liver(D)=GI, liver, kidney

ADME = Absorption, Distribution, Metabolism, Elimination

# Transcriptomics


Transcriptional perturbations and apical endpoints for both cancer and noncancer are evaluated in same organ tissues following short-term (e.g., 2-week) exposures





- Transcriptional pathway-based points-of-departure (PODs) from short-term in vivo assays were within 2-3 fold of both non-cancer (A) and cancer (B) apical PODs across different species, routes of exposure, durations of exposure, and target organ tissues
- Major challenge: relevance of transcriptional pathway perturbations to target organ toxicity?

# **GSEA:** Identifying Biologically-Relevant **Transcriptional Alterations**





(Image courtesy of Dr. Jeffry Dean, EPA/ORD/NCEA-Cincinnati)

The views expressed in this poster are those of the author and do not necessarily represent the views or policies of the U.S. Environmental Protection Agency


High-throughput Bioactivity

Integration of in vitro biological activity data (e.g., ToxCast/Tox21) and reverse toxicokinetic in vitro to in vivo extrapolation may facilitate identification of oral equivalent doses that can be benchmark dose modeled for identification of HTPbased PODs





### **HHRA** application(s)



(Wetmore et al., 2012, Tox Sci 125(1):157-174)

• Superfund Technical Support memos to EPA Regions; bioactivity information used as qualitative support for augmenting weight-of-evidence in analog(s) selection